Lucy Cook

Dr. Lucy Cook is an Honorary Clinical Senior Lecturer in the Department of Immunology and Inflammation at the Faculty of Medicine, Imperial College London. She also serves as a Consultant Haematologist at Hammersmith Hospital & St Mary's Hospitals, London (Imperial College Healthcare NHS Trust), specializing in the management of patients with lymphoproliferative disorders.

Her educational background includes a PhD from Imperial College Healthcare Charity (2010-2013), an MB BS from St Mary's Hospital Medical School (1995-2001), and a First Class BSc (Hons) from St Mary's Hospital Medical School (1997-1998).

• Professional Certifications:
  • FRCPath, Royal College Pathologists (2009-present)
  • MRCP, Royal College of Physicians, London (2004-present)

Dr. Cook's research primarily focuses on HTLV-1 and associated adult T-cell leukemia/lymphoma (ATL). She leads a national clinical service and HTLV diagnostic molecular lab. Her specific research interests include understanding which HTLV carriers develop leukemia/lymphoma, whether we can predict and intervene prior to disease development, and why not all carriers transform to malignancy.

Her scholarly work spans immunology, virology, oncology, and hematology, with a particular emphasis on lymphoproliferative disorders. Dr. Cook's recent publications demonstrate a strong focus on HTLV-1 pathogenesis, diagnostic approaches, and treatment strategies for adult T-cell leukemia/lymphoma, with emerging work on precision immunotherapies like CAR-iNKT cells and non-invasive monitoring techniques using liquid biopsy.

Scientific Awards and Recognitions:

• No specific awards mentioned in the available information

Dr. Cook is actively involved in clinical practice and research related to hematology, with a special focus on the intersection of virology and oncology. She contributes to both patient care through her consultant role and academic advancement through her position at Imperial College London, with particular emphasis on translating research findings into improved clinical outcomes for patients with HTLV-1 associated conditions.